INS and fatty liver disease: Moreover, amlexanox treatment in two different mouse models of obesity (HFD- induced and leptin-resistant ob/ob mice) resulted in improved insulin sensitivity, attenuated hepatic steatosis, reduced adipose tissue inflammation, and promoted energy expenditure in adipose tissue through increased thermogenesis [11].